Pages that link to "Q34414647"
Jump to navigation
Jump to search
The following pages link to MHC antigens and tumor escape from immune surveillance (Q34414647):
Displaying 50 items.
- Natural selection of tumor variants in the generation of "tumor escape" phenotypes (Q24551158) (← links)
- The urgent need to recover MHC class I in cancers for effective immunotherapy (Q26770165) (← links)
- Allogeneic tumor cell vaccines: the promise and limitations in clinical trials (Q26852333) (← links)
- MHC class I antigen processing and presenting machinery: organization, function, and defects in tumor cells (Q26866479) (← links)
- A novel category of antigens enabling CTL immunity to tumor escape variants: Cinderella antigens (Q27023313) (← links)
- Cancer immunoprevention: tracking down persistent tumor antigens (Q28205027) (← links)
- Vaccines for tumour prevention (Q28299036) (← links)
- Principles of cancer therapy: oncogene and non-oncogene addiction (Q29616779) (← links)
- Analysis of HLA-ABC locus-specific transcription in normal tissues. (Q33692969) (← links)
- HLA-G expression is an independent predictor for improved survival in high grade ovarian carcinomas (Q33758727) (← links)
- Microenvironment, oncoantigens, and antitumor vaccination: lessons learned from BALB-neuT mice (Q33786788) (← links)
- Quantification of HLA class I molecules on renal cell carcinoma using Edman degradation (Q33798689) (← links)
- The tumour suppressor Fhit positively regulates MHC class I expression on cancer cells (Q34208784) (← links)
- Recognition of tumors by the innate immune system and natural killer cells (Q34496462) (← links)
- The development of immunotherapies for non-small cell lung cancer (Q34560660) (← links)
- MHC class I loss is a frequent mechanism of immune escape in papillary thyroid cancer that is reversed by interferon and selumetinib treatment in vitro (Q34615021) (← links)
- Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction (Q35005940) (← links)
- Immunoprevention of colorectal cancer: a future possibility? (Q35029033) (← links)
- Immunology and immunotherapy of colorectal cancer (Q35097710) (← links)
- Cytokines reinstate NK cell-mediated cancer immunosurveillance (Q35140082) (← links)
- Cytokine therapy reverses NK cell anergy in MHC-deficient tumors (Q35140125) (← links)
- Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells. (Q35799094) (← links)
- Mechanisms of tumor evasion from the immune response. (Q35875302) (← links)
- Natural killer cells: role in local tumor growth and metastasis (Q35905953) (← links)
- Dendritic cell-based immunotherapy of malignant gliomas (Q35922426) (← links)
- Immunological aspects of head and neck cancer: biology, pathophysiology and therapeutic mechanisms. (Q35967042) (← links)
- Natural killer cells: can they be useful as adoptive immunotherapy for cancer? (Q36065944) (← links)
- Classical and nonclassical HLA class I antigen and NK Cell-activating ligand changes in malignant cells: current challenges and future directions (Q36083431) (← links)
- Immunotherapy of Metastatic Colorectal Cancer: Prevailing Challenges and New Perspectives. (Q36114649) (← links)
- Regression of melanoma metastases after immunotherapy is associated with activation of antigen presentation and interferon-mediated rejection genes (Q36419244) (← links)
- Immunosurveillance and immunotherapy of tumors by innate immune cells (Q36471212) (← links)
- Immunodominance and immunodomination: critical factors in developing effective CD8+ T-cell-based cancer vaccines (Q36543806) (← links)
- The correlation between colorectal cancer rates of proliferation and apoptosis and systemic cytokine levels; plus their influence upon survival (Q36614234) (← links)
- Spontaneous regression of colorectal cancer: a review of cases from 1900 to 2005. (Q36674018) (← links)
- MHC class I antigens and immune surveillance in transformed cells. (Q36714774) (← links)
- IFN inducibility of major histocompatibility antigens in tumors (Q37341021) (← links)
- Human leukocyte antigen class I expression is an independent prognostic factor in advanced ovarian cancer resistant to first-line platinum chemotherapy (Q37401538) (← links)
- Tumour infiltrating host cells and their significance for hyperthermia. (Q37730088) (← links)
- MUC1 immunotherapy. (Q37773241) (← links)
- Melanoma immunotherapy: historical precedents, recent successes and future prospects. (Q38081911) (← links)
- NK cell self tolerance, responsiveness and missing self recognition (Q38196030) (← links)
- Allogeneic chimeric antigen receptor-modified cells for adoptive cell therapy of cancer (Q38198742) (← links)
- HLA-E: a novel player for histocompatibility (Q38268679) (← links)
- Generation of MHC class I diversity in primary tumors and selection of the malignant phenotype. (Q38282541) (← links)
- Cancer immunotherapy: nanodelivery approaches for immune cell targeting and tracking (Q38288055) (← links)
- The delicate balance of melanoma immunotherapy (Q38288116) (← links)
- Cytokine therapy restores antitumor responses of NK cells rendered anergic in MHC I-deficient tumors (Q38564238) (← links)
- Radiation-induced loss of cell surface CD47 enhances immune-mediated clearance of human papillomavirus-positive cancer (Q38590722) (← links)
- Inactivation of class II transactivator by DNA methylation and histone deacetylation associated with absence of HLA-DR induction by interferon-gamma in haematopoietic tumour cells (Q38806235) (← links)
- From therapeutic antibodies to chimeric antigen receptors (CARs): making better CARs based on antigen-binding domain. (Q38951943) (← links)